Aurinia Pharmaceuticals Inc.
AUPH
$12.27
$0.191.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.41% | 24.18% | 32.76% | 24.32% | 37.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.41% | 24.18% | 32.76% | 24.32% | 37.83% |
| Cost of Revenue | 11.99% | 7.62% | -12.57% | -55.42% | -8.61% |
| Gross Profit | 25.47% | 30.13% | 56.79% | 71.90% | 62.03% |
| SG&A Expenses | -42.10% | -57.36% | -26.04% | -11.29% | -4.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3,288.28% | 207.37% | -56.08% | 72.93% | 92.01% |
| Total Operating Expenses | -13.57% | -31.28% | -24.37% | -20.85% | -0.05% |
| Operating Income | 4,679.82% | 455.86% | 132.73% | 172.24% | 97.27% |
| Income Before Tax | 1,399.05% | 343.25% | 104.44% | 212.61% | 112.18% |
| Income Tax Expenses | -14.95% | 35.99% | -155.77% | 53.36% | 217.76% |
| Earnings from Continuing Operations | 2,879.64% | 317.17% | 105.32% | 206.72% | 106.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,879.64% | 317.17% | 105.32% | 206.72% | 106.28% |
| EBIT | 4,679.82% | 455.86% | 132.73% | 172.24% | 97.27% |
| EBITDA | 469.31% | 1,738.77% | 167.17% | 251.27% | 128.49% |
| EPS Basic | 3,090.00% | 325.20% | 105.37% | 206.59% | 106.21% |
| Normalized Basic EPS | 829.73% | 908.33% | 162.86% | 212.52% | 120.90% |
| EPS Diluted | 3,090.00% | 314.48% | 105.37% | 206.27% | 106.21% |
| Normalized Diluted EPS | 811.71% | 884.72% | 160.52% | 210.43% | 120.90% |
| Average Basic Shares Outstanding | -5.90% | -3.54% | -0.52% | 0.14% | 0.39% |
| Average Diluted Shares Outstanding | -4.57% | -0.57% | 3.32% | 1.96% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |